

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 February 2002 (07.02.2002)

PCT

(10) International Publication Number
WO 02/09610 A1

(51) International Patent Classification⁷: **A61B 18/24, A61N 5/06**

(81) Designated States (*international*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(21) International Application Number: **PCT/US01/23887**

(22) International Filing Date: **30 July 2001 (30.07.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
09/629,242 31 July 2000 (31.07.2000) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 09/629,242 (CIP)
Filed on 31 July 2000 (31.07.2000)

(71) Applicant (*for all designated States except US*): **EPI-COR, INC. [US/US]; 240 Santa Ana Court, Sunnyvale, CA 94085 (US).**


(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **PLESS, Benjamin, D. [US/US]; 5 Ridgeview Dr., Atherton, CA 94027 (US).**

(74) Agents: **WHEELOCK, Thomas, E. et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).**

(54) Title: **PROCEDURES FOR PHOTODYNAMIC CARDIAC ABLATION THERAPY AND DEVICES FOR THOSE PROCEDURES**

WO 02/09610 A1



(57) Abstract: This relates to procedures and to devices for treating cardiac tissue by forming lesions in that tissue using photodynamic therapy techniques. In particular, the procedure is valuable for rectifying various cardiac arrhythmias with those so-formed lesions. Central to this procedure is the delivery of light to the desired lesion site in cooperation with delivery of a photodynamic drug to that site. The invention also relates to devices, particularly catheters, that are suitable for delivering the light for forming those lesions.

**PROCEDURES FOR PHOTODYNAMIC CARDIAC ABLATION THERAPY AND
DEVICES FOR THOSE PROCEDURES**

5

Field of the Invention

10 This invention relates to procedures and to devices for treating cardiac tissue by forming lesions in that tissue using photodynamic therapy techniques. In particular, the procedure is valuable for rectifying various cardiac arrhythmias with those so-formed lesions. Central to this procedure is the delivery of light to the desired lesion site in cooperation with delivery of a photodynamic drug to that site. The invention also relates to 15 devices, particularly catheters, that are suitable for delivering the light for forming those lesions.

Background of the invention

20 Many abnormal medical conditions in humans and other mammals have been associated with disease and other aberrations along the lining or walls of blood vessels. Treatment of such abnormal wall conditions has included various medical device technologies that deliver various forms of energy to specific regions of vascular wall tissue.

25 For instance, atherosclerosis, a vascular disease characterized by abnormal deposits upon vessel walls or the thickening of those walls, is an example of an abnormal wall condition. The dangers related to flow blockages or functional occlusions resulting from the disease have made atherosclerosis the focus of many medical devices. Such devices are often categorized by structure and tissue treatment mechanism. The categories include direct contact electrode devices, resistance heating devices, light transmission devices,

light-to-heat conversion devices, hot fluid devices, and radio frequency (RF) heated devices.

The first category includes a variety of contact electrode devices. For instance, U.S. Patent No. 4,998,933, to Eggers et al, describes a catheter for thermal angioplasty using a 5 heated electrode in direct contact with surrounding tissue or plaque deposits. The heated electrode serves to treat the diseased lumen walls. U.S. Patent Nos. 4,676,258, to Inokuchi et al, and 4,807,620, to Strul et al, disclose devices designed to treat surrounding tissues using heat generated by two electrodes within the device and an RF power source.

U.S. Patent Nos. 4,672,962, to Hershenson, and 5,035,694, to Kasprzyk et al, 10 disclose devices which may be categorized as resistance heating probes. In each of these devices, current flowing through a conductive material at the end of the device provides heat that is transmitted to surrounding tissues for treatment of atherosclerosis and other diseases. Current is transmitted in each of these devices by electrically conductive materials. In contrast, U.S. Patent No. 5,226,430, to Spears et al, discloses a device which 15 uses light transmitting fiber to transmit energy to a heat generating element at the tip of the device. That heat generating element in turn transmits heat energy to a surrounding balloon structure which is in contact with surrounding tissue. Similarly, U.S. Patent No. 4,790,311, to Ruiz, discloses an angioplasty catheter system having heat generating electrode at the tip of the device that is heated using RF energy. This device may be categorized as an RF 20 heated device.

U.S. Patent Nos. 5,190,540 and 5,292,321, to Lee, describe hot fluid-containing devices. Lee '540 shows a balloon catheter designed for remodeling a body lumen. This catheter uses a multilumen shaft that delivers a heated fluid to an expandable balloon. The expanded balloon heats the tissue that is in contact with the expanded balloon. Lee '321 25 shows a somewhat similar device. However, the expandable balloon is instead filled with a

selected thermoplastic material that becomes softer and more compliant when heated by a heating element.

Diseased or structurally damaged blood vessels often involve various abnormal wall conditions. The inducement of thrombosis and control of hemorrhaging within such 5 vessels have been the focus of several devices that use catheter-based heat sources for cauterizing damaged tissues. U.S. Patent No. 4,449,528, to Auth et al, discloses a thermal cautery probe designed for heating specific layers of tissue without producing deep tissue damage. The mechanism of heat generation in this device is a resistive coil within the cautery probe that is electrically connected to a power source. U.S. Patent No. 4,662,368, 10 to Hussein et al, discloses a device designed for localized heat application within a lumen. In this device, energy in the form of light is delivered to the tip of the device for heat generation, by a flexible fiber. Heat from an element that converts light energy to heat energy passes to the adjacent tissue.

Although there are a variety of devices that deliver energy to vascular lumina, none 15 of them deliver the energy in the form of light which cooperatively forms lesions in cardiac tissue using photodynamic chemicals to treat that cardiac tissue and to prevent various forms of fibrillation.

ATRIAL FIBRILLATION

20 Cardiac arrhythmias, and atrial fibrillation in particular, are common, dangerous medical ailments, particularly in the aging population. In patients with normal sinus rhythm, the heart, which is made up of atrial, ventricular, and excitatory conduction tissue, is electrically excited to beat in a synchronous, patterned fashion. In patients with cardiac arrhythmia, regions of cardiac tissue do not follow the synchronous beating cycle 25 associated with normally conductive tissue in patients with sinus rhythm. Instead, the

abnormal regions of cardiac tissue aberrantly conduct to adjacent tissue, thereby disrupting the cardiac cycle into an asynchronous cardiac rhythm. Such abnormal conduction generally occurs at various, specific regions of the heart, for example: in the region of the sino-atrial (SA) node, along the conduction pathways of the atrioventricular (AV) node and 5 the Bundle of His, or in the cardiac muscle tissue forming the walls of the ventricular and atrial cardiac chambers.

Cardiac arrhythmias, including atrial arrhythmia, may be of a multiwavelet re-entrant type, characterized by multiple asynchronous loops of electrical impulses that are scattered about the atrial chamber. These arrhythmias are often self propagating. Cardiac 10 arrhythmias may also have a focal origin, such as when an isolated region of tissue in an atrium fires autonomously in a rapid, repetitive fashion. Cardiac arrhythmias, including atrial fibrillation, may be detected using the global technique of an electrocardiogram (EKG). More sensitive procedures of mapping the specific conduction along the cardiac 15 chambers have also been disclosed, such as for example in U.S. Patents No. 4,641,649 to Walinsky et al and WO 96/32897 to Desai.

A variety of clinical conditions may result from the irregular cardiac function and resulting hemodynamic abnormalities associated with atrial fibrillation, including stroke, heart failure, and other thromboembolic events. Atrial fibrillation is believed to be a significant cause of cerebral stroke; the abnormal hemodynamics in the left atrium caused 20 by the fibrillatory wall motion precipitate the formation of thrombus within the atrial chamber. A thromboembolism is ultimately thrown off into the left ventricle, which then pumps the embolism into the cerebral circulation causing a stroke. For these reasons, there are a number of procedures for treating atrial arrhythmias.

Conventional Atrial Arrhythmia Treatments

There are several pharmacological approaches intended to remedy or otherwise treat atrial arrhythmias. See, for example, U.S. Patent No. 4,673,563, to Berne et al; U.S. Patent No. 4,569,801, to Molloy et al; and Hindricks, et al in "Current Management of 5 Arrhythmias" (1991). However, such pharmacological solutions are not always effective and may in some cases result in proarrhythmia and long term inefficacy.

Several surgical approaches have been developed to treat atrial fibrillation. One example is known as the "maze procedure," as is disclosed by Cox, J.L. et al in "The surgical treatment of atrial fibrillation. I. Summary" *Thoracic and Cardiovascular Surgery* 101(3), pp. 402-405 (1991); and also by Cox, J.L. in "The surgical treatment of atrial fibrillation. IV. Surgical Technique", *Thoracic and Cardiovascular Surgery* 101(4), pp. 584-592 (1991). In general, the "maze" procedure is designed to relieve atrial arrhythmia by restoring effective atrial systole and sinus node control via a specific pattern of incisions in the tissue wall. Early on, the "maze" procedure included surgical incisions in both the 15 right and the left atrial chambers. However, more recent reports predict that the surgical "maze" procedure may be effective when performed only in the left atrium. See, Sueda et al, "Simple Left Atrial Procedure for Chronic Atrial Fibrillation Associated With Mitral Valve Disease" (1996).

The "maze procedure" as surgically performed in the left atrium generally includes 20 forming vertical incisions from the two superior pulmonary veins and terminating in the region of the mitral valve annulus, traversing the inferior pulmonary veins en route. An additional horizontal incision also connects the superior ends of the two vertical incisions. The atrial wall region bordered by the pulmonary vein ostia is therefore isolated from the other atrial tissue. In this way, the mechanical sectioning of atrial tissue eliminates the

precipitating conduction to the atrial arrhythmia by creating conduction blocks within the aberrant electrical conduction pathways.

Although the "maze" procedure is generally effective, it is a highly invasive procedure. Nevertheless, the procedures have provided a guiding principle for alleviating 5 arrhythmia: the mechanical isolation of faulty cardiac tissue often prevents atrial arrhythmia, and particularly atrial fibrillation caused by perpetually wandering reentrant wavelets or focal regions of arrhythmogenic conduction.

Modern Catheter Treatments for Atrial Arrhythmia

10 Success with surgical interventions through atrial segmentation, particularly with regard to the surgical "maze" procedure just described, has caused others to develop less invasive catheter-based approaches to treat atrial fibrillation through cardiac tissue ablation. Examples of such catheter-based devices and treatment methods have generally targeted atrial segmentation with ablation catheter devices and methods adapted to form linear or 15 curvilinear lesions in the wall tissue which defines the atrial chambers, such as are disclosed in the following: U.S. Patent No. 5,617,854, to Munsif; U.S. Patent No. 4,898,591, to Jang et al; U.S. Patent No. 5,487,385, to Avitall; and U.S. Patent No. 5,582,609 to Swanson.

Additional examples of catheter-based tissue ablation in performing less-invasive 20 cardiac chamber segmentation procedures are also disclosed in the following articles: "Physics and Engineering of Transcatheter Tissue Ablation", Avitall et al., *Journal of American College of Cardiology*, Volume 22, No. 3:921-932 (1993); and "Right and Left Atrial Radiofrequency Catheter Therapy of Paroxysmal Atrial Fibrillation," Haissaguerre, et al., *Journal of Cardiovascular Electrophysiology* 7(12), pp. 1132-1144 (1996).

Furthermore, various energy delivery modalities (microwave, laser, and more commonly, RF) is used to create conduction blocks (atrial wall lesions) along the cardiac tissue wall. See, WO 93/20767, to Stern et al; U.S. Patent No. 5,104,393, to Isner et al; and U.S. Patent No. 5,575,766, to Swartz et al.

5 Additionally, ablation catheter devices and methods have also been used to ablate arrhythmogenic tissue of the left-sided accessory pathways, such as those associated with the Wolff-Parkinson-White syndrome, through the wall of an adjacent region along the coronary sinus.

For example, Fram et al, in "Feasibility of RF Powered Thermal Balloon Ablation
10 of Atrioventricular Bypass Tracts via the Coronary Sinus: *In vivo* Canine Studies," *PACE*, Vol. 18, p 1518-1530 (1995), discloses attempted thermal ablation of left-sided accessory pathways in dogs using a balloon which is heated with bipolar radiofrequency electrodes positioned within the balloon. Fram et al suggests that the lesion depth of some population groups may be sufficient to treat patients with Wolff-Parkinson-White syndrome.

15 Additional examples of cardiac tissue ablation from the region of the coronary sinus for the purpose of treating particular types of cardiac arrhythmias are disclosed in: "Long-term effects of percutaneous laser balloon ablation from the canine coronary sinus", Schugger CD et al., *Circulation* (1992) 86:947-954; and "Percutaneous laser balloon coagulation of accessory pathways", McMath LP et al., *Diagn. Ther. Cardiovasc. Interven.* 20 1991; 1425:165-171.

Focal Arrhythmias Originating from Pulmonary Veins

Atrial fibrillation may be focal in nature, caused by the rapid and repetitive firing of an isolated center within the atrial cardiac muscle tissue. These foci, defined by regions exhibiting a concentric pattern of electrical activation, may act either to trigger atrial

fibrillation or to sustain the fibrillation. Some studies have suggested that focal arrhythmia often originates from a tissue region along the pulmonary veins of the left atrium, and even more particularly in the superior pulmonary veins.

Less-invasive percutaneous catheter ablation techniques have been disclosed which

5 use end-electrode catheter designs with the intention of ablating and thereby treating focal arrhythmias in the pulmonary veins. These ablation procedures are typically characterized by the incremental application of electrical energy to the tissue to form focal lesions designed to interrupt the inappropriate conduction pathways.

One example of a focal ablation method intended to destroy and thereby treat focal

10 arrhythmia originating from a pulmonary vein is disclosed by Haissaguerre et al, "Right and Left Atrial Radiofrequency Catheter Therapy of Paroxysmal Atrial Fibrillation," *Journal of Cardiovascular Electrophysiology* 7(12), pp. 1132-1144 (1996). Haissaguerre et al discloses radiofrequency catheter ablation of drug-refractory paroxysmal atrial fibrillation using linear atrial lesions complemented by focal ablation targeted at

15 arrhythmogenic foci. The site of the arrhythmogenic foci were generally located just inside the superior pulmonary vein.

In another focal ablation example, Jais et al. in "A focal source of atrial fibrillation treated by discrete radiofrequency ablation" *Circulation* 95:572-576 (1997) discusses the use of an RF ablative technique to patients with paroxysmal arrhythmias originating from

20 focal sources variously in both the right and left atria.

None of the cited references discloses a procedure or assembly for creating lesions in cardiac tissue using a light source in cooperation with photoactivatable chemical compounds to form lesions or conduction blocks about focal arrhythmias.

Central to the invention disclosed here is the use of photodynamic therapy (PDT)

25 techniques to create lesions having the same function as those discussed just above. The

inventive methods are significantly less invasive; specifically, the lesions may be created without surgery, without the use of any cardiac bypass procedures, and without the use of heat.

5

PHOTODYNAMIC THERAPY

There are a variety of medical procedures requiring administration of light or irradiated energy to a patient within the body. One such example is the use of a light activated compound selectively to kill target cells in a patient; as noted above, such therapy is often termed photodynamic therapy ("PDT"). In such PDT methods, a light-activated 10 drug is injected into a patient and a targeted light source is used selectively to activate the drug. When activated by light of a proper wavelength, the light-activated drug produces a toxic, often cytotoxic, agent that mediates the destruction of the surrounding cells or tissue.

Currently, the major application of PDT is for the destruction of malignant cell masses. PDT has been used effectively in the treatment of a variety of human tumors and 15 precancerous conditions including basal and squamous cells, skin cancers, breast cancer, metastatic skin cancers, brain tumors, head and neck cancers, stomach cancers, and female genital tract malignancy, cancers and precancerous conditions of the esophagus such as Barrett's esophagus. A review of the history and progress of PDT is provided by Marcus, S. Photodynamic Therapy of Human Cancer: Clinical Status, Potential, and Needs. In 20 Gomer, C. J. (ed.); "Future Directions and Applications in Photodynamic Therapy." Bellingham, W. A. SPIE Optical Engineering Press (1990) pp 5-56. Specific applications of PDT are provided by Overholt et al., Sem. Surg. Oncol. 11:1-5 (1995).

The use of various porphyrin compounds as the photoactivated compounds in such treatments is known. These treatments are often tumor-selective in that selected porphyrin 25 compounds accumulate at higher concentrations in tumor tissue than in normal tissue.

In general, the PDT procedure involves administration of a sensitizer compound (such as the porphyrin derivatives) to the target tissue and a subsequent step involving the application of light to that tissue. The PDT procedures function selectively to eradicate diseased tissue in the immediate area of the light source by generating singlet oxygen and

5 activated molecules which damage tissue in that immediate area. Selectivity is attained through the preferential retention of the photosensitizer in rapidly metabolizing tissue such as tumors (Kessel, David, "Tumor Localization and Photosensitization by Derivatives of Hematoporphyrin. A Review" IEEE J. QUANTUM ELECTRON., QE 23(10): 1718-20 (1987)); virally infected cells (J. Chapman et al, "Inactivation of Viruses in Red Cell

10 Concentrates with the Photo Sensitizer Benzoporphyrin Derivative (BPD)", TRANSFUSION 31(suppl): 47S Abstract S172, (1991) and J. North et al., "Viral Inactivation in Blood and Red Cell Concentrates with Benzoporphyrin Derivative", Blood Cells, 18: 129-140 (1992)); leukaemic cells (C. H. Jamieson, "Preferential Uptake of Benzoporphyrin Derivative by Leukaemic versus Normal Cells", Leuk. Res. (England) 15 1990, 14 (3), pp 209-210); psoriatic plaque (M. W. Reems et al, "Response of Psoriasis to Red Laser Light (630 nm) Following Systemic Injection of Hematoporphyrin Derivative", Lasers Surg Med. 1984, 4(1) pp73-77); and atherosclerotic plaque (S. Andersson-Engels et al, "Fluorescence Diagnosis and Photochemical Treatment of Diseased Tissue Using Lasers: Part II", Anal. Chem. 62(1), 19A-27A (1990). The activation of the photosensitizer

15 by light occurs only at the site at which the light is present. Obviously, the photo-sensitizer-mediated destruction of tissue occurs only at the desired treatment site. The non-activated photosensitizer is substantially nontoxic and will eventually be cleared from the body.

In a typical PDT treatment, PHOTOFRIN.RTM. porfimer sodium, BPD, or BPD-

25 MA is injected into a patient. See, for instance, Ho et al., "Activity and Physicochemical

Properties of PHOTOFRIN.RTM.", Photochemistry and Photobiology, 54(1), pp83-87 (1991); U.S. Pat. No. 4,866,168, to Dougherty et al. An appropriate dose is, e.g., 0.25-2.5 mg/kg of body weight, depending upon the diseased tissue and the choice of photosensitizer. At an appropriate time after photosensitizer administration, the diseased 5 tissue or site is illuminated with a light source at an appropriate wavelength (630 nm for PHOTOFRIN.RTM. and 690 nm for BPD) to activate the photosensitizer. The light-activated drug induces the formation of singlet oxygen and free radicals which damage the surrounding tissue. Both the diseased tissue and the vasculature feeding it are affected and the unwanted tissue is either directly destroyed or starved of oxygen and nutrients due to 10 the occlusion of blood vessels. After the completion of the PDT, the treated tissue becomes necrotic and will either debride naturally or be debrided by the clinician.

Hematoporphyrin and PHOTOFRIN.RTM. have absorption spectra in the neighborhood of 630 nm. The absorption spectra of much blood and tissue is also in the same general spectral region. Consequently, much of the energy impinging upon the 15 treated tissue is absorbed in the tissue itself, thereby limiting, in a practical sense, the physical depth to which the PDT treatment using hematoporphyrin and PHOTOFRIN.RTM. may be used. BPD-MA has an absorption spectra with peaks in longer wavelength regions, e.g., 690 nm. These compounds are viewed as improvements to the PDT treatment method in that the tissues do not absorb so much of the light energy and 20 therefore allow increased depth of light penetration.

It has been the desire and the practice in PDT treatment to provide uniform illumination in a chosen treatment area.

Allardice et al., Gastrointestinal Endoscopy 35:548-551 (1989) and Rowland et al, PCT application WO 90/00914, disclose a light delivery system designed for use with PDT. 25 The disclosed system involves a flexible tube having a dilator and a transparent treatment

window that defines a treatment area by using opaque end-caps made of stainless steel. A fiber optic element that is connected to a laser and ends in a diffusing tip is used in combination with the dilator to deliver light to a tissue source. Allardice et al suggests that the advantages of this apparatus over the use of balloon-type catheter reside in providing a
5 more uniform distribution of light.

Nseyo et al, Urology 36:398-402 (1990) and Lundahl, U.S. Pat. Nos. 4,998,930 and 5,125,925, disclose a balloon catheter device for providing uniform light radiation to the inner walls of hollow organs. The device is a balloon catheter design having a balloon at one end of the apparatus and an optical fiber ending in a diffusion tip that is inserted into
10 the lumen of the balloon through the catheter. The catheter's centering tube is said to provide a more uniform distribution of the laser light by centering the optical fiber in the inflated balloon. These catheter devices further incorporate optical sensing fibers in the balloon wall to allow measurement of the resulting illumination.

Panjehpour et al, Lasers and Surgery in Medicine 12:631-638 (1992) discloses the
15 use of a centering balloon catheter for esophageal PDT. Panjehpour et al discloses a cylindrical balloon catheter into which a fiber optic probe ending in a light diffuser is inserted.

Overholt et al, Lasers and Surgery in Medicine 14:27-33 (1994) discloses various structures similar to the balloon catheter device described in Panjehpour et al. Overholt et
20 al's includes a black opaque coating on both ends of the balloon to define a 360° treatment window. Overholt et al additionally describes a modified balloon in which one-half of the circumference of the treatment window is rendered opaque to light using the black coating material. This configuration provides a 180° treatment window.

Rowland et al, PCT application WO 90/00420, discloses a light-delivery system for
25 irradiating a surface. The device has a hemispherical shell in which the inside is entirely

coated with a diffuse reflector. A light source is mounted within the shell. The light source may contain a diffusing source at the tip allowing diffusion of light within the reflective shell.

U.S. Pat. No. 5,344,419, to Spears, discloses devices and methods for making laser-
5 balloon catheters. Spears uses a process that etches an end of a fiber optic cable to provide a diffusion tip on that optical cable. The optical cable containing the etched tip is secured within a central channel of a balloon catheter using a coating of adhesive containing microballoons. The position of the tip within the central channel and the microballoons contained in the adhesive provide increased efficiency in diffusing the laser radiation in a
10 cylindrical pattern, providing uniform illumination at the target site.

U.S. Pat. No. 5,354,293, to Beyer et al, discloses a balloon catheter for delivering light for use in PDT. That balloon catheter employs a conical tipped fiber optic cable for deflecting a light beam radially outward through a transparent portion of an inflated balloon.

15 Although various of the disclosures discussed above provide ways for providing light to a target site, none of them suggest a procedure for creating lesions in cardiac tissue using PDT, particularly for control of cardiac arrhythmia, nor do they suggest endovascular light-delivery devices that are specifically configured to provide limited lineal or circumferential lesions in cardiac tissue.

20

Summary of the invention

This invention relates to methods for producing lesions in cardiac tissue by the step of subjecting cardiac tissue containing a photodynamic drug to a light source in a predetermined pattern to form a lesion corresponding to that predetermined pattern.

Normally, the step of forming the lesions is heat-free. The method may also include the step of introducing the photodynamic drug, locally or systemically, to the cardiac tissue.

Preferably the selected, predetermined pattern is one which limits, controls, or prevents cardiac arrhythmia. Among the preferred predetermined patterns are those which 5 encircle the pulmonary vein bed in the left atrium and those which encircle at least one or of superior pulmonary veins in the left atrium

The procedure may apply the lesions to the cardiac tissue from the exterior of the heart, e.g., through the epicardium or via a surgical or an endovascular procedure to the interior of the heart.

10 The preferred light delivery device, i.e., for providing light to the selected cardiac tissue, comprises a generally linear member having a distal region with an axis. That distal region preferably includes a substantially clear and linear light emitting region corresponding to said axis. The light emitting region is preferably bendable to conform to curved cardiac tissue. That light emitting region generally emits all of the light emanating 15 from said device and may be, e.g., a window or lens or at least one LED.

Brief Description of the Drawings

Figure 1 shows a cutaway of the left atrium of a human heart and the lesion path created in the "maze" procedure as produced by the inventive procedure.

20 Figure 2 also shows a cutaway of the left atrium of a human heart and the circumferential lesion path created in the os of the superior pulmonary veins as produced by the inventive procedure.

Figures 3A and 3B show respectively side and top views of a light application device in accord with this invention.

Figures 4A and 4B show respectively top and side views of a light application device using LED's made according to the invention.

Figure 5 shows a plan view of a light application catheter made according to the invention.

5 Figure 6 shows a step in the application of light through the epicardium in creating lesions for one predetermined pattern for alleviating arrhythmia.

Figure 7 shows a step in the application of light through the epicardium in creating lesions for a second predetermined pattern for alleviating arrhythmia.

10

Detailed description of the Invention

As noted above, many of the currently available ablation techniques use heat to create a lesion in cardiac tissue. Further, since many of the known techniques are quite invasive, the normal but substantial risks associated with heart surgery and the allied equipment are also present. In any case, the heat typically used to produce the lesions is generated by RF current, ultrasound, laser, or microwaves. The generation of heat has the potential to damage non-target tissues and to cause blood coagulation that sometimes results in embolic events. Such embolic events are particularly dangerous when ablating cardiac tissue on the left side of the heart because of the potential for embolic stroke. This invention uses a combination of a photodynamic drug, often systemically administered, and the application of light to the chosen cardiac tissue to create a lesion in that cardiac tissue without using heat. The lesion is a region of tissue that due to the inventive process no longer has significant electrophysiological activity. The lesion does not conduct the cardiac pulse and acts as a block to the fibrillating waves. Therefore, a properly constructed set of lesions terminates fibrillation and makes it highly unlikely that the atria will sustain a fibrillation.

By "photodynamic drug" is meant a photosensitizer that absorbs light over a range of frequencies and produces a chemical reaction, preferably one producing a toxin or other actor capable of creating the desired lesion. Examples of these photodynamic drugs and their sources include: BOPP (boronated porphyrin) from Pacific Pharmaceutical, FOSCAN 5 from Scotia QuantaNova, PHOTOFRIN (dihematoporphyrin ether also known as DHE) from QLT PhotoTherapeutic, and ANTRIN from Pharmacyclic. For many photosensitizers the wavelength of light used for sensitization is in the range of 405 to 630 nm. The photodynamic effect is stronger at shorter wavelengths, but longer wavelengths penetrate tissue more effectively, so light near 630 nm is preferred. The choice of wavelength is also 10 dependent upon the choice of specific photosensitizers. The light may be from a white light source (e.g. a xenon lamp), from lasers (preferably an argon dye laser), or from LEDs. When the light is absorbed by a photosensitizer, it produces an unstable energy state that ultimately results in the generation of an excited singlet oxygen. An excited singlet oxygen is chemically highly reactive and is toxic to tissue.

15 In the inventive procedure, a patient is given the photodynamic drug prior to the ablation or lesion-producing step. During the procedure, a catheter or other device containing a light source, or light guides (e.g., using fiber optics) connected to a light source, is placed on the exterior or in the interior of the heart in the area that the physician desires a lesion. The chosen region of the heart is then illuminated with this high intensity 20 light, triggering the photodynamic reaction in the localized area where the lesion is desired. The lesion is created without the generation of heat, and preferably the light is shielded from non-target tissues. As a result the ablation or lesion-producing procedure is safer than current techniques.

The inventive procedure may be used in a variety of ways; the light may be 25 introduced onto the cardiac tissue either from points exterior to the heart or from the

interior to the heart. The use of the inventive process allows the creation of fairly deep lesions extending from the epicardium to the endocardium without damaging delicate vessels. In contrast, one major drawback of RF ablation is that since it primarily heats the surface under a current carrying electrode, it is not possible to create deep lesions from the 5 epicardium beneath blood vessels without damaging those vessels.

The patient is first treated, e.g., by intravenous injection or local administration, with a dose of a photodynamic drug. The drug remains inactive until it is activated by a light source.

This choice of a specific photosensitizing drug is not central to this invention; the 10 chosen drug is used in combination with a device to deliver light to the heart to create a lesion, primarily to control or to abolish cardiac arrhythmias of any sort. If the photosensitizer is given systemically, the patient generally must avoid direct sunlight for a period of time after such administration. To avoid or to lessen the impact of this side effect, the photosensitizer may be applied topically or locally to the area of the heart which 15 is to be ablated. This may be done using a separate device from the light delivery device, or in the preferred embodiment, the photosensitizer is incorporated in the light delivery device.

In one variation of the inventive procedure, the primary arrhythmia to be cured is atrial fibrillation. Figure 1 shows a partial cross-section of a left atrium (100) of a human 20 heart. The superior pulmonary veins (102, 104), the mitral valve annulus (106), and the inferior pulmonary veins (108, 110) are also depicted. Figure 1 also shows the "maze" procedure discussed in the Cox article discussed above is depicted using the procedure of the invention. Specifically created are: a lesion (112) extending from the os of the superior pulmonary vein (104) by the os of the inferior pulmonary vein (108) and to the mitral valve 25 annulus (106), a second lesion (114) extending from the os of the superior pulmonary vein

(102) by the os of the inferior pulmonary vein (110) and to the mitral valve annulus (106), and a third lesion (116) between the os of the two superior pulmonary veins (102, 104).

Figure 2 shows the same view of the heart as found in Figure 1, the difference being the circumferential lesions (118, 120) created using the inventive procedure respectively in 5 the os of the superior pulmonary veins (104, 102). This procedure is explained with greater particularity in U.S. Pat. No. 6,024,740, to Lesh et al, at least when performed with RF as the ablation energy.

Again, it should be understood that once the photosensitizing chemical is applied to the cardiac region to be at which a lesion is to be formed, the light may be introduced either 10 from the interior or exterior of the heart. This is especially true in treating atrial fibrillation where the typical ectopic arrhythmic foci are accessible from the exterior. The application of light may be via an endovascular catheter, an endoscopic device, or by a device applied by hand or robot through a surgical opening.

Figures 3A and 3B show side and top views of a device (200) to deliver light from a 15 light source to the epicardium of the heart. A proximal port (202) on the device interfaces with an external light source. The light source may be, for instance, a xenon lamp, a high intensity LED source, laser, or any other source capable of producing illumination in the appropriate wavelengths, e.g., from 350 to 700nm. Fiber optics or other light guides extend inside a flexible housing (204) typically made of a polymeric material, to carry the light 20 from the port (202) to the distal end of the device. At the distal end, the light guide terminates in an elongated, generally linear window (or lens) (206) that allows the light to escape onto the heart surface. The back side of the window is opaque to ensure that no light escapes to reach tissues other than those targeted by the physician. To modify the area of tissue that is illuminated, the window (206) may obviously be manufactured in

different sizes or may be shuttered by the application of an opaque adhesive tape (208) or other material.

In the alternative, the device (200) may be configured so that individual strands of the fibers in the fiber optic cable are tied to individual portions of the window(206). Some 5 portion of the proximal ends of the individual fibers in the fiber optic cable available at the proximal connector (202), may be selectively blocked from the light source to cause less of the window (206) to be illuminated.

Figures 4A and 4B show top and side views of a device (230) having light emitting devices (generally light emitting diodes or LED's) (232) on the distal end, that deliver light, 10 e.g., to the epicardium of the heart. The proximal connector (234) connects to the light emitting devices (232) through electrical conductors (236). The light emitting devices (232) are preferably light emitting diodes (LED's) that emit light around 600 nanometers which penetrates tissue well. Again, the back side of the device is opaque to assure that only tissues that are targeted for ablation receive light.

15 For some cardiac procedures, a device that delivers light to the inside of the heart (endocardially) is preferred. Figure 5 shows a catheter-based device (300) configured to introduce light into the heart to activate a photosensitizing drug. The proximal connector (302) is adapted to connect to an external light source. Fiber optics or other light guides (304) carry the light through the flexible catheter body (306) to the clear distal window (308). The back side of the window is opaque to assure that only tissues that are intended 20 for ablation receive light. Design of the catheter body to provide close contact between the distal window or lens (308) with the interior heart wall to produce a narrow and clean-edged lesion is within the scope of the ordinary catheter designed in the art. The distal window (308) may also be a spot rather than a linear window and moved along the cardiac

tissue at an appropriate rate to produce a lesion. Suitable lesion patterns for controlling atrial fibrillation are depicted in Figs. 1 and 2.

Again, methods of controlling atrial fibrillation include creation of a lesion either encircling the pulmonary vein bed or around the superior pulmonary arteries in the left 5 atrium.

Figure 6 shows the device of variously of Figures 2A, 2B, 3A, or 3B in one position producing a first portion of a lesion around the pulmonary vein bed. The procedure involves placement of the light-emitting device (400) along the left atrium (402) between the left inferior (404) and superior (406) pulmonary veins and the right inferior (408) and 10 superior (410) pulmonary veins. The device may be placed encircling the vein bed or, as shown, be sequentially placed eventually to encircle the veins.

Similarly, Figure 7 shows the placement of the device (400) of variously of Figures 2A, 2B, 3A, or 3B in two positions (400(a)) and (400(b)) on the epicardium, each producing portions of a lesion encircling the bases of the superior pulmonary veins (406, 15 410) in a procedure analogous to that discussed in Lesh et al above.

I CLAIM AS MY INVENTION:

1. A method for producing lesions in cardiac tissue comprising the step of subjecting a cardiac tissue containing a photodynamic drug to a light source in a predetermined pattern to form a lesion corresponding to that predetermined pattern.
5
2. The method of claim 1 further comprising the step of introducing said photodynamic drug to said cardiac tissue.
3. The method of claim 2 wherein said introducing step comprises systemic introduction of said photodynamic drug to a patient having said cardiac tissue.
10
4. The method of claim 2 wherein said introducing step comprises local introduction of said photodynamic drug to said cardiac tissue.
5. The method of claim 1 wherein said predetermined pattern encircles an ectopic arrhythmic focus in said cardiac tissue.
15
6. The method of claim 1 wherein said predetermined pattern encircles the pulmonary vein bed in the left atrium of a patient having said cardiac tissue.
20
7. The method of claim 1 wherein said predetermined pattern encircles at least one or of superior pulmonary veins in the left atrium of a patient having said cardiac tissue.
8. The method of claim 1 wherein said predetermined pattern is exterior to a heart containing said cardiac tissue.
25

9. The method of claim 8 wherein said light delivery is through an epicardium.
10. The method of claim 1 wherein said predetermined pattern is interior to a heart containing said cardiac tissue.
11. A method for the heat-free treatment of a selected cardiac tissue comprising the step of subjecting said cardiac tissue containing a photodynamic drug to a light source to form a lesion.

10

12. The method of claim 11 further comprising the step of introducing said photodynamic drug to said cardiac tissue.
13. The method of claim 12 wherein said introducing step comprises systemic introduction of said photodynamic drug to a patient having said cardiac tissue.
14. The method of claim 12 wherein said introducing step comprises local introduction of said photodynamic drug to said cardiac tissue.
- 20 15. The method of claim 11 wherein said step of subjecting said cardiac tissue containing a photodynamic drug to a light source to form a lesion comprises forming a predetermined pattern on said cardiac tissue.
- 25 16. The method of claim 15 wherein said predetermined pattern encircles an ectopic arrhythmic focus in said cardiac tissue.

17. The method of claim 15 wherein said predetermined pattern encircles the pulmonary vein bed in the left atrium of a patient having said cardiac tissue.

5 18. The method of claim 15 wherein said predetermined pattern encircles at least one or of superior pulmonary veins in the left atrium of a patient having said cardiac tissue.

19. The method of claim 15 wherein said predetermined pattern is exterior to a
10 heart containing said cardiac tissue.

20. The method of claim 11 wherein said step of subjecting said cardiac tissue containing a photodynamic drug to a light source to form a lesion comprises delivering said light through an epicardium.

15
21. The method of claim 11 wherein said step of subjecting said cardiac tissue containing a photodynamic drug to a light source to form a lesion comprises delivering said light interior to a heart containing said cardiac tissue.

20 22. A light delivery device for providing light to a cardiac tissue comprising a generally linear member having a distal region with an axis, said distal region having a substantially clear and linear light emitting region corresponding to said axis, said light emitting region being conformable to a curved cardiac tissue.

23. The light delivery device of claim 22 wherein said light emitting region emits all light emanating from said device.

24. The light delivery device of claim 22 wherein said light emitting region
5 comprises a window or lens.

25. The light delivery device of claim 22 wherein said light emitting region comprises at least one LED.

1/5




FIG. 1

2/5






FIG. 2

3/5



4/5




FIG. 4A




FIG. 4B




FIG. 5

5/5

FIG. 6





FIG. 7



INTERNATIONAL SEARCH REPORT

In National Application No
PCT/US 01/23887

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61B18/24 A61N5/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61B A61N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 800 478 A (CHEN JAMES C ET AL) 1 September 1998 (1998-09-01) column 4, line 41-52 column 8, line 63-65; figures 1,16C,23,44,48 ---	22,23,25
X	US 5 671 314 A (HAW THOMAS E ET AL) 23 September 1997 (1997-09-23) column 1, paragraphs 1,2 column 3, line 38-50; figure 1A ---	22-24
X	WO 92 17243 A (ARIA CORP) 15 October 1992 (1992-10-15) page 1, line 4-7 page 15, line 3-20; figure 6 ---	22-24
	-/-	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
17 December 2001	03/01/2002

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Reinbold, F

INTERNATIONAL SEARCH REPORT

In	onal Application No
PCT/US 01/23887	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 403 308 A (WOOD LEROY ET AL) 4 April 1995 (1995-04-04) column 1, line 20-25; figure 10 —	22-24
X	WO 99 15236 A (PHARMACYCLICS INC ;ORTIZ MARK V (US)) 1 April 1999 (1999-04-01) page 1, line 25-30 page 10, line 22-26; figure 7A —	22,23,25
X	US 5 169 395 A (NARCISO JR HUGH L) 8 December 1992 (1992-12-08) column 5, line 27-29 column 6, line 26-35; figure 7 —	22,23
X	US 5 824 005 A (WARE DAVID L ET AL) 20 October 1998 (1998-10-20) column 2, line 3-5 column 4, line 10-37; figure 4A —	22,23
E	US 2001/037080 A1 (MUELLER RICHARD L ET AL) 1 November 2001 (2001-11-01) paragraphs '0006!, '0007!, '0013!, '0028!; figures 6A-6H —	22-24

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/23887

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
US 5800478	A	01-09-1998	AU	708410 B2		05-08-1999
			AU	2128297 A		22-09-1997
			AU	721857 B2		13-07-2000
			AU	2499099 A		22-07-1999
			CA	2244957 A1		12-09-1997
			CN	1217638 A		26-05-1999
			EP	0884972 A1		23-12-1998
			JP	11507284 T		29-06-1999
			NO	984077 A		03-11-1998
			WO	9732520 A1		12-09-1997
			US	5766234 A		16-06-1998
US 5671314	A	23-09-1997		NONE		
WO 9217243	A	15-10-1992	AU	1870592 A		02-11-1992
			DE	69226634 D1		17-09-1998
			DE	69226634 T2		04-03-1999
			EP	1116476 A2		18-07-2001
			EP	0582686 A1		16-02-1994
			EP	0792663 A2		03-09-1997
			EP	0792664 A2		03-09-1997
			JP	6509949 T		10-11-1994
			WO	9217243 A2		15-10-1992
US 5403308	A	04-04-1995	US	5190536 A		02-03-1993
			US	5111821 A		12-05-1992
			CA	2002559 A1		08-05-1990
			US	5062431 A		05-11-1991
			US	5205291 A		27-04-1993
WO 9915236	A	01-04-1999	US	6096030 A		01-08-2000
			AU	9486698 A		12-04-1999
			EP	1017450 A1		12-07-2000
			JP	2001517507 T		09-10-2001
			WO	9915236 A1		01-04-1999
US 5169395	A	08-12-1992		NONE		
US 5824005	A	20-10-1998	AU	737479 B2		23-08-2001
			AU	6850396 A		19-03-1997
			CN	1193267 A		16-09-1998
			EP	0957758 A1		24-11-1999
			JP	11511999 T		19-10-1999
			US	6143019 A		07-11-2000
			WO	9707735 A1		06-03-1997
US 2001037080	A1	01-11-2001		NONE		

THIS PAGE BLANK (USPTO)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 February 2002 (07.02.2002)

PCT

(10) International Publication Number
WO 02/09811 A1

(51) International Patent Classification⁷: **A61N 2/02** Adrian, R., M.: 78 Highland Park Drive, Dundas, Ontario L9H 6G8 (CA).

(21) International Application Number: **PCT/US01/23958**

(74) Agent: **WIXON, Clarke**: NeuroPace, Inc., 255 Santa Ana Court, Sunnyvale, CA 94085 (US).

(22) International Filing Date: **31 July 2001 (31.07.2001)**

(81) Designated States (*national*): **CA, JP.**

(25) Filing Language: **English** (84) Designated States (*regional*): European patent (DE, FR, GB).

MIGRAINE HEADACHE TREATMENT APPARATUS

5

FIELD OF THE INVENTION

10 This invention is in the field of medical devices for the treatment of migraine headaches.

BACKGROUND OF THE INVENTION

15 Migraine headaches occur in approximately 12% of the world population. Therefore, in the United States in the year 2000 there are approximately 30 million people who suffer from this affliction. Although medicines have been created that significantly diminish the suffering of migraine patients, the medicines often have highly undesirable side effects and many patients do not obtain satisfactory relief from the severe headache pain and other 20 discomforts associated with migraine. Furthermore, migraine headaches are typically treated after they have become painful, i.e., the treatment is often ineffective in preventing the onset of the migraine headache. Other than some drugs for some patients, there is no known treatment for migraine headaches that can be applied after a patient detects an aura of that headache to prevent the occurrence of pain and other undesirable manifestations of that 25 migraine headache. A non-invasive, non-drug method for preventing the occurrence of migraine headaches would be a remarkable boon for those millions of people all over the world who suffer from these painful experiences.

In 1985, A.T. Barker, et al (*Lancet*, 1985, pp. 1105-1107) described the use of a coil placed over the scalp which produced a high intensity, time varying, magnetic field. This 30 magnetic field produces an electric current in the cortex of the human brain which can in turn produce certain effects on brain neurons. By the year 2000, this type of system was given the name Transcranial Magnetic Stimulation (TMS). If repetitive magnetic pulses are applied in this manner, it has been given the name rTMS.

In the journal Neurology (April 11, 2000, pp. 1529-1531), it has been reported by B. Boroojerdi, et al that rTMS at a rate of one pulse per second can create a reduction of the excitability of the neurons of the human visual cortex. However, no known references have indicated that rTMS can be used for the preventing the occurrence of migraine headaches.

5

SUMMARY OF THE INVENTION

This invention is a means and method for the treatment of migraine headaches for those patients who experience a distinct aura before the actual occurrence of the symptoms of the migraine headache. It is estimated that approximately 40% of all migraine patients have a distinct aura that is a precursor of a migraine headache. Approximately half of these patients have a visual aura that typically begins as a small pattern of scintillating colored lights that have the appearance of wiggling worms. Over a time period of between 20 and 30 minutes, the pattern enlarges until it occupies nearly the entire visual field. During this time period, the patient might also completely lose part of his visual field. At the end of this visual aura, most migraine patients have a severe headache that is often accompanied by other symptoms such as nausea, vomiting and other unpleasant feelings. Many migraine patients who do not have a visual aura have some other precursor of a migraine that can be perceived from minutes to hours before the actual start of the headache.

The visual aura is a result of the spatial progression of a band of brain cells that are excited in that band across one half of the brain's occipital lobe. This band moves in an anterior direction at the rate of approximately 2-5 mm per minute. It is this excited band of neurons of the brain that produces the scintillating colored lights that are perceived by the patient as an aura that is a precursor of a migraine headache. Behind this leading band of excited neurons, a spreading region of neurons with depressed electrical excitability occurs. This phenomenon is known as "the spreading depression of Leao".

It is believed that if the advancing band of excited neurons can be stopped before the aura has completed its 20 to 30 minute time duration period, the migraine headache will not occur. One way to stop such an advancing band of excited brain neurons would be by imposing a high enough electric current through these neurons so that they become depolarized. This could be accomplished by means of electrodes placed on the brain's surface at the occipital lobe (i.e., the visual cortex). If these electrodes would have at least several millamps of electrical current placed across them, the excited neurons could be

depolarized, thus eliminating their enhanced excitability. However, this would require surgery to implant such electrodes. Also, a neurostimulator attached by wires to the electrodes would be required, which neurostimulator would be adapted to place a voltage across the electrodes to cause the flow of a sufficiently high electrical current to depolarize the advancing band of excited neurons.

The invention disclosed herein is a non-invasive, externally applied device that is placed on or near the patient's head in the region of the brain where the aura originates (e.g., the occipital lobe) as soon as possible after the patient becomes aware of a visual (or any other type) aura that is a precursor of the migraine headache. For patients whose aura originates from a region of the cerebral cortex that is not the occipital lobe, the depolarizing device can be applied to that region of the brain. By the use of a high intensity alternating magnetic field, a sufficiently high electrical current can be placed onto the advancing band of excited neurons so as to depolarize those neurons thereby terminating the aura before it is able to progress into a migraine headache. Depolarization of neurons in advance of the advancing band of excited neurons may also be used to prevent a migraine headache. This is because depolarized neurons become refractory after rTMS is applied. This is analogous to cutting down or burning the trees in front of a forest fire in order to prevent the spread of that forest fire.

The one pulse per second of rTMS described by Boroojerdi, et al, which was proven to cause a reduction of cerebral cortex excitability, could be applied to break up the advancing band of excited neurons that is the cause of the visible aura of a migraine headache. Since an aura has a time duration that is typically at least 20 minutes, the patient has a sufficient time period for placing the rTMS magnetic depolarizer in the appropriate position for it to be effective in depolarizing the advancing band of excited brain neurons.

It should also be noted that stimulation of the scalp might also have an effect in preventing or decreasing the severity of a migraine headache for at least some patients. Scalp stimulation may act as a conditioning response that becomes associated with the migraine process. Pairing this response with rTMS may provide cessation of the migraine process with progressively less intensity of magnetic stimulation.

Since the band of excited neurons that create a visual aura moves from the back of the head in an anterior direction, and since either the left or right half of the occipital lobe might be involved, the magnetic depolarizer would optimally be placed along the posterior-anterior centerline at the top of the head. If it is known that a particular patient has the spreading

depression on either the right or the left half of the occipital lobe, then the magnetic depolarizer might be placed only on that region where the spreading depression occurs. If the aura originates from a part of the cerebral cortex that is not the occipital lobe, then the alternating magnetic field can be appropriately placed to depolarize neurons in that location.

5 It is expected that the patient can be trained to recognize the symptoms from a particular area of the brain so that the magnetic depolarizer can be placed in an optimum location to prevent the occurrence of a migraine headache.

The magnetic depolarizer can be formed in a race-track, figure-eight shape with its long axis placed along the head's posterior-anterior centerline. The width of the magnetic depolarizer might be between 1 and 10 cm and its height in a direction above the skull could be between 0.5 to 5 cm. The length of magnetic depolarizer would typically be between 3 and 15 cm. The magnetic depolarizer could be placed within some form of head covering such as a bicycle helmet. A rechargeable battery and electronic circuitry to generate the required alternating magnetic field could also be contained within a helmet type of head gear.

10 15 A conventional AC adapter (recharging device) could be provided to the patient for recharging the battery of the magnetic depolarizer system.

A sufficiently intense alternating magnetic field must be created that would cause the excited band of brain neurons to be depolarized before this band has a chance to create a migraine headache. The intensity of the magnetic field at the surface of the brain should be between 0.1 and 10 Tesla. The frequency rate of the magnetic pulses should be between 0.1Hz and 1.0 kHz. With some patients a single, short duration pulse may be all that is required to stop an advancing band of excited neurons from proceeding to a full-blown migraine headache. The magnetic pulses can be applied continuously for a period of between 0.1 and 100 seconds. By applying a time varying magnetic field to the neurons of the cerebral cortex (and also to the neurons in the scalp), a patient could be able to actually prevent the occurrence of a migraine headache.

Thus, an objective of this invention is to prevent the occurrence of a migraine headache by creating a high intensity, time varying magnetic field by means of a magnetic depolarizer placed onto the scalp of a patient who has an aura which is a precursor of a migraine headache, the magnetic depolarizer being adapted to cause depolarization of the neurons in the cerebral cortex where the aura originates.

Another object of this invention is to have the magnetic depolarizer placed inside a headgear that the patient can place on his or her head, the headgear being adapted to place the magnetic depolarizer at a specific location relative to the patient's cerebral cortex.

Still another object of the invention is to have a magnetic depolarizer system that 5 includes a battery, electronic circuitry (including a magnetic depolarizer) for creating a high intensity, time varying magnetic field, a patient operated ON-OFF switch and settings of the system's operating parameters that are set by a physician.

Still another object of the invention is to have the magnetic depolarizer system use a rechargeable battery.

10 These and other objects and advantages of this invention will become obvious to a person of ordinary skill in this art upon reading the detailed description of this invention including the associated drawings as presented herein.

BRIEF DESCRIPTION OF THE DRAWINGS

15

FIGS. 1-3 are an illustration of how a band of excitable neurons spreads across the occipital lobe of a human brain.

FIG. 4 is a cross section of the present invention showing a magnetic depolarizer system within a helmet on the head of a migraine patient.

20

FIG. 5 is a longitudinal cross section of the magnetic depolarizer.

FIG. 6 is a top view of the magnetic depolarizer.

FIG. 7 is a simplified circuit diagram of the main components of a magnetic depolarizer system.

25

DETAILED DESCRIPTION OF THE INVENTION

FIGS. 1-3 illustrate a time sequence of events associated with a visual aura of a migraine headache. Initially, the brain 1 experiences a band 3 of brain neurons in an excited state. The region 2 of the brain 1 has neurons in a normal state of excitation while the region 30 4 has neurons that are in depressed state of excitation. As the aura of the migraine headache continues in time, the band 3 shown in FIG. 1 advances at a rate between 2-5 mm per minute in a direction shown by the arrow 5. In FIG. 2, we see that the band 3 has advanced in an anterior direction, and the region 4 of depressed neurons has become enlarged. Finally, in

FIG. 3, we see that the depressed region 4 has spread to occupy a majority of the neurons of the visual cortex (i.e., the occipital lobe). This phenomenon is known as "spreading depression". With a typical patient, the duration during which spreading depression occurs is between 20 and 30 minutes.

5 FIG. 4 illustrates the head of a migraine patient showing a cross section of the magnetic depolarizer system 10 as it would be contained within a helmet 11 of the type used by bicycle riders. The magnetic depolarizer system 10 consists of a magnetic depolarizer 12, a battery 14, electronic circuitry 15, a recharging receptacle 16 and interconnecting wires 17. The magnetic depolarizer system 10 is contained within the helmet 11 by means of an elastic support 13 that passes between a front support 11A and a rear support 11B. The purpose of the elastic support 13 is to keep the magnetic depolarizer coil 12 in comparatively tight contact with the top and back of the patient's head and at a specific location relative to the patient's cerebral cortex.

10

15 FIG. 5 is a longitudinal cross section of the magnetic depolarizer 12 of FIG. 4. The magnetic depolarizer 12 consists of a first coil 21 placed into a figure-eight configuration with a second coil 22. The two coils 21 and 22 are electrically connected in series in such a way as to create north magnetic poles 21A and 22A in essentially opposite directions when electric current is flowing through the coils 21 and 22. This orientation of coils 21 and 22 can produce a comparatively strong magnetic field onto the cortex of the brain for a distance 20 of a few centimeters beneath the cranium. If the magnetic field changes rapidly in time, it produces an electric current in the visual cortex that can cause the advancing band 3 (of FIGS. 1-2) of excited neurons (or neurons in front of the advancing band) to be depolarized thus preventing the spreading depression phenomenon from continuing. If the spreading depression can be halted, it is likely that at least some migraine patients will not develop a 25 migraine headache or possibly the headache will be less severe.

Because the helmet 11 containing the magnetic depolarizer system 10 can be kept in reasonably close proximity to the patient at all times, it would be reasonable to assume that the patient can place the helmet 11 appropriately in less than the 20 to 30 minutes that is the time period during which the pre-migraine aura occurs. It should also be understood that the 30 patient could use one or more elastic bands (without a helmet) to place the magnetic depolarizer at an appropriate location onto his or her head.

FIG. 6 is a top view of the magnetic depolarizer 12 showing as dotted lines the outline of the coils 21 and 22. In both FIGS. 5 and 6, it is shown that the coils 21 and 22 could be

encapsulated into a plastic housing 25. Furthermore, FIG. 5 shows a magnetic core 23 in the coil 21 and a separate magnetic core 24 in the coil 22. These cores 23 and 24 are not required for the device to perform its intended purpose of generating a depolarizing electric current within the cerebral cortex, but they could be used to provide the same magnetic field intensity in the brain at a lower level of electric current in the coils 21 and 22. To be effective at the high frequency of the magnetic pulses that are used to stimulate the cortex, the cores 23 and 24 would typically be formed from powdered iron or equivalent ferromagnetic material that has low eddy current and hysteresis losses.

Although FIGS. 5 and 6 show a race-track, figure eight type of design for the magnetic depolarizer 12, it should be understood that a simple cylindrical coil (and other shaped coils as well) with or without a ferromagnetic core could be used generate the desired time-varying magnetic field.

FIG. 7 is a simplified electrical diagram of the magnetic depolarizer system 10. The rechargeable battery 14 can be recharged through the receptacle 16 that can receive a plug from a conventional AC adapter (not shown) that connects to AC line voltage (e.g., 115 volts) and delivers an appropriate DC voltage to recharge the rechargeable battery 14. An adapter for utilizing a car or boat 12-volt battery for operating the magnetic depolarizer system 12 is also envisioned. When the patient is experiencing an aura of a migraine headache, he or she can throw the ON-OFF switch 29 to the ON position. That would cause the DC-to-DC converter 30 to come on and generate a high voltage for rapidly charging the capacitor 26. When the control circuitry 28 senses that the appropriate voltage has been reached, it moves the switch 27 from position A to position B thus discharging the capacitor 26 through the coils 21 and 22 of the magnetic depolarizer 12. As previously described, the coils 21 and 22 could have air cores or they could use magnetically permeable cores 23 and 24. The control circuitry 28 can be used to set the repetition rate for causing magnetic pulses to be delivered. For example, a pulse from the capacitor might last for 70 microseconds and could be repeated at a frequency rate between 0.1 and 100 Hz. A frequency of 1.0 Hz has been shown to be effective in depolarizing brain neurons and may be ideal for some migraine patients. However, other patients might find other repetition rates to be more effective. It is even possible that a single magnetic pulse having a time duration between 10 and 1,000 microseconds could be used to stop an aura thereby preventing the occurrence of a migraine headache.

Although FIGS. 4 and 7 show a battery operated magnetic depolarizer system 10, the system 10 could be operated by plugging into a receptacle at (typically) 115 or 230 volts AC. Such a system might or might not use a battery as part of its circuitry.

It should be understood that in order to be useful to a migraine patient, the magnetic depolarizer system 10 must have several distinct characteristics that are different from currently available systems for repetitive Transcranial Magnetic Stimulation (rTMS). Specifically, the inventive concept of the present invention includes the fact that the magnetic depolarizer system 10 is readily portable, has preset operating parameters that are not adjustable by the patient, can be placed on the patient's head by the patient and is turned on and off by the patient. "Readily portable" can be defined as having a weight of less than 15 kg. The only presently known rTMS equipment (the Cadwell MES-10) is operated by a physician and not by a patient, has operational parameters that are adjustable by the physician as it is being used (i.e., the parameters are not preset), has a magnetic coil that is placed on a patient by an attending physician, and since the entire system weighs 34 kg it is certainly not readily portable so as to be with the patient wherever he or she might need it. To be useful for its intended purpose, the magnetic depolarizer system 10 would have operating parameters that are preset by an attending physician. These operating parameters can include one or more of the following attributes: the peak intensity of the magnetic field at a distance of 1.0 cm beneath the magnetic depolarizer; the time period of each magnetic pulse; the repetition rate of the magnetic pulses; the total number of pulses to be delivered when the magnetic depolarizer system is turned on; and the location of the magnetic depolarizer within a helmet into which the magnetic depolarizer is placed. Once these parameters are set, the patient would operate the system 10 by placing it on his or her head and then turning the system on and then off after the aura of a migraine headache has been terminated. It may be desirable for the patient to turn the system on but a timer would automatically turn the system off after a preset period of time.

Since the aura of a migraine headache might occur at any time, and since the patient may have only 20 minutes to use the magnetic depolarizer system 10, each patient would want to have a system in relatively close proximity. For example, the patient would want to have the system at home, and/or at work, and/or in his or her car. The magnetic depolarizer system would optimally be sufficiently portable to be taken with the patient on a vacation or on a business trip.

It is also envisioned that the magnetic depolarizer system could include a memory for recording various parameters of the magnetic depolarizer system including the setting of the magnetic field intensity. Within a limited range, it is envisioned that the patient could set different levels for the magnetic field intensity in order to determine that level that is most effective in preventing a migraine headache. It is further envisioned that the magnetic depolarizer system as described herein could be used for the treatment of other disorders such as depression, pain, epilepsy, bipolar disease and other disorders of the brain.

Various other modifications, adaptations and alternative designs are of course possible in light of the teachings as presented herein. Therefore, it should be understood that, while still remaining within the scope and meaning of the appended claims, this invention could be practiced in a manner other than that which is specifically described herein.

What is claimed is:

1. A magnetic depolarizer system for the treatment of migraine headache, the system comprising:

5

a readily portable magnetic depolarizer adapted for placement at a specific location onto the head of a human being, the magnetic depolarizer having a least one electromagnetic coil that is capable of providing a time varying magnetic field having a peak intensity at some portion of the patient's cerebral cortex of at least 0.1 Tesla;

10

electrical circuitry connected to the magnetic depolarizer for providing an electrical current through the at least one electromagnetic coil, the electrical circuitry also including a patient operated switch for turning on the magnetic depolarizer system; and,

15

a positioner adapted to affix the magnetic depolarizer system onto a specific region of the head of the human being.

2. The system of claim 1 wherein the electrical circuitry of the magnetic depolarizer system includes a battery.

20

3. The system of claim 2 wherein the battery is rechargeable.

4. The system of claim 1 wherein the magnetic depolarizer includes at least two coils, in a race-track, figure-eight configuration.

25

5. The system of claim 1 wherein the magnetic depolarizer includes at least one ferromagnetic core.

30

6. The system of claim 1 wherein the electronic circuitry is adapted to deliver at least one time varying magnetic pulse.

7. The system of claim 6 wherein the length of the magnetic pulse is between approximately 1 microsecond and approximately 1,000 microseconds.

8. The system of claim 6 wherein the electronic circuitry is adapted to deliver a sequence of pulses comprising a plurality of time varying magnetic pulses, and wherein the magnetic pulses are delivered at a rate of between approximately 0.1 Hz and
5 approximately 1,000 Hz.
9. The system of claim 8 wherein the sequence of pulses is delivered over a time period of between approximately 0.1 second and approximately 100 seconds.
10. 10. The system of claim 1 wherein the positioner comprises a headgear adapted to accurately place the magnetic depolarizer at a specific location on the head of the human being.
11. The system of claim 10 wherein the headgear comprises a helmet of the type worn by
15 bicycle riders.
12. The system of claim 10 wherein the headgear comprises at least one elastic band.
13. The system of claim 1, wherein the electrical circuitry also includes at least one
20 operating parameter that is preset by a physician
14. A system for the treatment of a migraine headache in a patient, the system comprising:
25 a readily portable magnetic depolarizer adapted for placement at a specific location onto the head of the patient, wherein the magnetic depolarizer is capable of providing a time varying magnetic field having a peak intensity at some portion of the patient's cerebral cortex of at least 0.1 Tesla;
- 30 a patient-operated switch for activating the magnetic depolarizer; and
a positioner for placing the magnetic depolarizer onto a specific region of the head of the patient.

1/4




FIG. 1




FIG. 2




FIG. 3




FIG. 4

3/4




FIG. 5




FIG. 6

4/4




FIG. 7

INTERNATIONAL SEARCH REPORT

Inte [redacted] Application No
PCT/US 01/23958A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61N2/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 06342 A (EPSTEIN CHARLES M ;DAVEY KENT R (US); NEOTONUS INC (US)) 19 February 1998 (1998-02-19) page 6, line 17 -page 8, line 28; figures	1,14
A	DE 198 15 900 A (WOLFF FRIEDRICH) 1 July 1999 (1999-07-01) column 1, line 51 -column 7, line 42; figures	1,14
A	GB 2 271 931 A (SACKS BENJAMIN ISRAEL ;RUDOLF NOEL (GB)) 4 May 1994 (1994-05-04) page 3, line 1 -page 5, line 9; figures	1,14
A	US 5 738 625 A (GLUCK DANIEL S) 14 April 1998 (1998-04-14) column 3, line 16 -column 4, line 30; figures	1,14

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

26 November 2001

Date of mailing of the international search report

30/11/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
 Fax (+31-70) 340-3016

Authorized officer

Rakotondrajaona, C

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l Application No

PCT/US 01/23958

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 9806342	A	19-02-1998	AU AU EP JP WO US	735591 B2 4158497 A 0930849 A1 2000504966 T 9806342 A1 6132361 A		12-07-2001 06-03-1998 28-07-1999 25-04-2000 19-02-1998 17-10-2000
DE 19815900	A	01-07-1999	DE WO	19815900 A1 9932191 A1		01-07-1999 01-07-1999
GB 2271931	A	04-05-1994	NONE			
US 5738625	A	14-04-1998	DE GB JP	4420233 A1 2278783 A 7143971 A		15-12-1994 14-12-1994 06-06-1995